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Amyloid cystic lung disease presenting in a patient 
with human immunodeficiency virus
Abstract
A 30-year-old gentleman with a medical history of HIV, on HAART therapy and pulmonary amyloidosis proven by lung biopsy 
presented with progressive, worsening shortness of breath and chronic productive cough over the last year. Pulmonary function 
tests showed a severely obstructive process and CT scan of the thorax manifested diffusely thin-walled, air-filled cysts. After 
reviewing the patient’s prior histories, PFTs and CTof the thorax, the most likely cause of his symptoms was amyloid-related cystic 
lung disease. After being placed on a LABA/ICS, and LAMA inhaler, the man’s condition remained stable. Active oncologic and 
pulmonary surveillance were continued every three to six months as the patient’s respiratory status, PFTs and imaging remained 
stable. Thoughts of chemotherapy and lung transplant have been suggested, but not initiated at this time.
Amyloid-related cystic lung disease is a rare presentation of amyloidosis in the thorax. It has been associated with collagen vas-
cular diseases and mucosa-associated lymphoid tissue lymphoma. After an extensive literature search, it does not appear that 
this condition has been referenced in an HIV-positive patient; thus making this report unique. More case reports will need to be 
published and reviewed to see whether an association with HIV and amyloid-associated cystic lung disease exists. 
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Introduction
Amyloidosis is a broad term used to charac-
terize extracellular tissue deposition of plasma 
proteins in a pathological insoluble fibrillar form 
[1]. These deposits can occur in many different 
organs and therefore cause a constellation of 
clinical conditions. Amyloid-related cystic lung 
disease is one of the rarer conditions in the 
thorax. At this time, it has been associated with 
collagen vascular diseases (most commonly be-
ing Sjörgen Syndrome) and mucosa-associated 
lymphoid tissue lymphoma (MALToma) [2]. After 
an extensive literature search, it does not appear 
that amyloid-related cystic lung disease has been 
referenced in a human immunodeficiency virus 
(HIV)-positive patient. 
Case presentation
A 30-year-old gentleman was referred to our 
pulmonary clinic in 2014 by his medical oncolo-
gist due to concerns of his worsening shortness of 
breath over the last year in the setting of pulmo-
nary amyloidosis proven by surgical lung biopsy 
two years earlier (Figure 1). His medical history 
was also significant for HIV with recent initiation 
of highly active antiretroviral therapy (HAART) 
and a recent cluster of differentiation 4 (CD4) 
count of 300. His HIV has been complicated by 
HIV-associated mucosa-associated lymphoid tis-
sue (MALT) lymphoma status post chemotherapy 
and pneumocystic pneumonia, both in August 
2013. He also had an 8-year history of smoking 
a pack per day but quit over a year earlier. 
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This was the patient’s first presentation to 
our pulmonary clinic. He described a history of 
a chronic cough that was productive in nature 
and worsening shortness of breath over the last 
year. The patient now finds he gets short of breath 
whenever he tries to minimally exert himself. At 
baseline, the patient qualified for 2 L of home 
oxygen, which he stated he wore throughout the 
night and usually around 4–5 hours during the 
day. He also noted an increased need for his al-
buterol inhaler, now requiring its use 4–5 times 
per week. The patient denied any orthopnea or 
paroxysmal nocturnal dyspnea with his short-
ness of breath. At the time of initial assessment 
in the clinic, the man was found to have normal 
vitals except mild tachypnea with a respiratory 
rate of 20; however, he had a peripheral oxygen 
saturation of 94% on room air. On physical exam 
he had a mild expiratory wheeze diffusely in both 
lung fields; otherwise, the rest of his physical 
examination was within normal limits. 
The patient recently had pulmonary function 
tests (PFTs), which showed a severely obstructive 
process. The forced expiratory volume 1 (FEV1) 
was 0.97 L (29% predicted), the forced expiratory 
volume 1 over forced vital capacity (FEV1/FVC) 
was 64% predicted, the total lung capacity (TLC) 
was 6.46 L (101% predicted) with no improve-
ment after bronchodilator, residual volume was 
4.24 L (232% predicted) and diffusion capacity 
of carbon monoxide (DLCO) was 15.2 mL/mm 
Hg/min (60% predicted).
In addition, the man had a recent computed 
tomography (CT) scan of his thorax that showed 
diffusely distributed thin-walled, air-filled cystic 
spaces which had increased in number since his 
previous CT scan two years earlier. A majority 
of the cystic spaces appeared to be centrilobular 
in distribution; however, they were also noted 
extending to the pleural surfaces and paraseptal 
locations. Lung apices also appeared to be less af-
fected than mid to lower lung segments. Scattered 
2-3mm nodules were redemonstrated compared to 
previous CT scans; however, the number of nod-
ules had decreased and were replaced by areas of 
cystic lung destruction (Figs 2, 3). There were no 
features consistent with bronchiolitis obliterans 
such as a mosaic pattern. A transthoracic echo-
cardiogram (TTE) revealed an ejection fraction 
of 55 to 60% with normal diastolic function. No 
abnormalities of cardiac leaflets or chambers 
were noted; right ventricle was normal in size, 
thickness and function, but unfortunately, no 
mention of right ventricular systolic pressure 
(RVSP) was noted. 
At this time, the working diagnosis was pul-
monary amyloidosis in the setting of HIV and 
HIV-associated MALT lymphoma causing obstruc-
tive symptoms clinically manifesting as shortness 
of breath and productive cough. However, there 
were plans to check alpha-1 antitrypsin level as 
this is also high on the differential. Due to the 
patient’s symptoms and evidence of wheezing 
on examination, the man had budesonide-formo-
terol fumarate added to his inhaled medication 
regimen. He continued to take his previously 
prescribed albuterol as needed. He was counseled 
to continue using his oxygen regularly, and he 
was referred to the Infectious Disease clinic for 
appropriate vaccinations. The patient was to fol-
low up pulmonary checkup every three months 
or for worsening symptoms.
The man continued to follow up in the pul-
monary clinic approximately every three months 
Figure 1. The section shows lung parenchyma with extensive pale pink, extracellular, glassy, hyaline material around the blood vessels. The congo 
red staining shows orange color of the amyloid deposits
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as requested. His alpha-1 antitrypsin level came 
back within normal limits. Despite adherence to 
the inhaler regimen of budesonide-formoterol fu-
marate used twice daily and albuterol as needed, 
the patient continued to have significant short-
ness of breath with minimal exertion and carried 
on with a productive cough. Due to poor symp-
tom control, aclidinium bromide was also added 
to his regimen. Again, the man had minimal, if 
any, improvement with these two scheduled in-
halers. Repeat PFTs were performed that showed 
a relatively stable severely obstructive process 
one year after initial visit with a FEV1 of 0.74 L 
from 0.97 L (29% to 22% predicted), a FEV1/FVC 
of 68% predicted (from 64% predicted), a TLC 
of 6.08 from 6.46 L (94% from 101% predict-
ed) with no improvement after bronchodilator, 
residual volume increasing to 4.36 from 4.24 L 
(from 232% predicted to 230% predicted) and 
a DLCO of 15.9 from 15.2 mL/mm Hg/min (from 
60% predicted to 57%). At this time, a discussion 
was held with the patient’s oncologist regarding 
the treatment of his pulmonary amyloidosis. The 
oncologist did not believe starting chemotherapy 
targeting plasma cells would help reverse his 
pulmonary status. Active oncologic and pulmo-
nary surveillance were continued every three to 
six months as the patient’s respiratory status and 
PFTs remained relatively stable. Referral for lung 
transplantation evaluation was discussed with 
the patient and he did not want to consider this 
option at this time. 
Discussion
Amyloidosis is a generic term to describe 
a group of disorders associated with the patho-
logical extracellular tissue deposition of plasma 
proteins in an insoluble fibrillar form. These 
deposits can occur in many different organs and 
therefore cause a constellation of clinical condi-
tions. Amyloid light-chain (AL) is the most com-
mon type of amyloidosis associated with thoracic 
involvement [3]. Other noncardiac intrathoracic 
amyloid-related patterns that have been described 
are: tracheobronchial, parenchymal with nodular 
and diffuse alveolar septal subtypes, intrathorac-
ic lymphadenopathy, parenchymal with diffuse 
alveolar septal subtype and pleural disease [4]. 
Amyloid-related cystic lung disease is one of the 
rarer conditions in the thorax. 
The pathomechanism of cyst formation in 
amyloidosis is not fully understood; however, 
at this time, the studies indicate that pulmonary 
elastolysis via elastolytic matrix metallopro-
teinases is the common denominator between 
cystic lung light chain deposition disease and 
other cystic lung diseases. It is postulated that 
initially, there is recruitment of macrophages 
around light chain deposits, which cause elastin 
destruction via the production of matrix metal-
loproteinases. This in turn causes fragility of the 
lung parenchyma and enlargement and rupture 
of the affected alveoli and bronchioles [5].
Knowledge regarding this disease is limited at 
this time as only a few case reports are available 
for review. After surveying twenty-one cases, the 
most common pulmonary function pattern seen 
were normal (42%) and obstructive (32%) [2]. Im-
aging reports for these cases typically found cysts 
that were: multiple defined as greater than or equal 
to 10 (67%), round (100%) or lobulated (95%); 
thin-walled defined as < 2 mm (81%), small 
defined as < 1 cm (100%) to moderate defined 
as 1–2 cm in size (81%) [2]. The most commonly 
Figure 2. Axial chest CT image showing diffuse cystic lesions with 
scattered micronodules
Figure 3. Coronal chest CT image showing diffuse cystic lesions with 
scattered micronodules
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associated diseases were collagen vascular dis-
eases (57%) and the most common being Sjörgen 
Syndrome (10 of the twelve cases). Pulmonary 
mucosa-associated lymphoid tissue lymphoma 
(MALToma) were also diagnosed in 33% of cases.
The major question then arises: how are we 
certain that the patient’s symptoms were second-
ary to this rare disease rather than a plethora of 
more common etiologies? The man’s differential 
diagnosis was very broad for his worsening 
shortness of breath. Emphysema could explain 
the patient’s symptoms; however, he only had 
an eight pack-year smoking history, which is 
unlikely to explain the severity of his symptoms, 
the degree of obstruction seen on PFTs and the 
amount of destruction seen on CT of the thorax. 
Other possibilities could be secondary to his 
HIV affecting his lungs; however, the patient was 
started on HAART therapy a few months earlier 
with appropriate response in both CD4 count 
and viral load, so that concern had already been 
addressed. Alpha-1 antitrypsin deficiency could 
also explain the symptoms; however, this was 
ruled out. Therefore, what remained was the pa-
tient’s pulmonary amyloidosis, which is known to 
cause an obstructive pattern on PFTs secondary to 
narrowing of the airways [2] and the evidence of 
cystic changes on thoracic CT, which are apparent 
in this patient. However, it is important to note 
the man’s history of pneumocystic pneumonia, 
which might have led to cystic changes in the 
lungs, however these usually are limited in num-
ber, resolve with time and are not associated with 
severe obstructive lung disease [6].
This report is unique as the patient is the first 
described in literature to have both amyloid-re-
lated cystic lung disease and HIV. More case 
reports will need to be published and reviewed 
to see whether an association between HIV and 
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